Our Pittsburgh risperdal attorneys at Chaffin Luhana represent individuals who have suffered serious injuries as a result of taking Risperdal (risperidone). An anti-psychotic medication prescribed for schizophrenia and other disorders, Risperdal has been linked with abnormal breast tissue growth in boys, diabetes, and other side effects for which the manufacturers failed to provide adequate warnings.
If you live in the Ohio Valley area and have had your life turned upside down because of Risperdal, contact our Chaffin Luhana Pittsburgh, PA dangerous drug attorneys for a free initial consultation. We can help you determine if you may be eligible to file a Risperdal lawsuit in an attempt to recover damages.
What is Risperdal?
Risperdal (rispiridone) was first approved by the FDA in 1993 to treat schizophrenia in adults. The agency went on to approve it for a number of other conditions, including:
In 2003 for the treatment of bipolar disorder.
In October 2006 for the treatment of irritability in autistic children and young adults.
In August 2007, to treat schizophrenia in children ages 13-17, as well as to treat bipolar disorder in children ages 10-17.
Risperdal Breast Development in Young Men
Risperdal was on the market for about a decade when doctors started raising concerns about Risperdal serious side effects in boys and young men. In 2006, a study by Duke University researchers showed that adolescents who took Risperdal exhibited significantly higher levels of “prolactin,” a hormone that stimulates breast development in women.
A 2007 study found that low-to-intermediate doses of risperidone induced a 4-fold prolactin increase in children. In 2008, the Wall Street Journal reported incidences of Risperdal breast development in young men (called gynecomastia), with some requiring mastectomies to treat the problem. A later study in 2009 found that after treatment with risperidone, elevated prolactin levels persisted for up to two years in children and adolescents.
Risperdal Serious Side Effects
Risperdal has also been linked with an increased risk of diabetes. In a 2003 study, researchers identified 131 reports of high blood sugar in patients taking the drug. A 2006 study confirmed that medications like Risperdal increased risk of new-onset diabetes in patients, and a later study published in 2013 also found that teens taking Risperdal face a three-fold risk for developing type 2 diabetes in the first year of treatment.
In April 2005, the FDA issued a Public Health Advisory stating that elderly patients treated with Risperdal were at an increased risk of death. They required the manufacturers to update their labels to describe this risk and noted that the drug was not approved for treating dementia-related psychosis.
At Chaffin Luhana in Pittsburgh, PA, our injury attorneys keep up with the current progress of Risperdal lawsuits across the country. Over 400 plaintiffs have brought claims against manufacturers Janssen Pharmaceuticals and parent company Johnson & Johnson (J&J), with over 100 of those concerning gynecomastia. We understand the difficulties faced by these plaintiffs, who have gone through unnecessary suffering and trauma because these companies failed to provide adequate information and warnings on their products.
A Risperdal mass tort has been formed in Philadelphia’s Court of Common Pleas, and already J&J has agreed to a handful of Risperdal settlements. The terms were kept confidential. Additional Risperdal lawsuits continue to make their way through the courts.
According to the New York Times, J&J has also agreed to pay more than $2.2 billion in criminal and civil fines related to its promotion of Risperdal—the third largest pharmaceutical settlement in U.S. history.
If you or a loved one were injured and you believe it may be associated with Risperdal, contact us today for a free consultation. We can help guide you through the legal process, and help determine your eligibility for a lawsuit.